Bayer Slumps as Bleak Crop Outlook Undermines Monsanto Rationale, , on October 1, 2020 at 7:15 am

By
On October 1, 2020
Tags:

(Bloomberg) — Bayer AG slumped after the agriculture and pharma giant said it would have to slash costs as the pandemic’s impact on farm commodities extends into next year, further undermining the rationale for its $63 billion purchase of Monsanto Co.The stock fell as much as 13% in German trading. Bayer, already reeling from a legal battle over its herbicide Roundup, late Wednesday said it would cut 1.5 billion euros ($1.8 billion) of annual costs and may also eliminate jobs and sell businesses.Chief Executive Officer Werner Baumann is confronting multiple challenges after getting his contract extended earlier this month. Besides Roundup, the German company faces slumping crop prices and demand for biofuel that threaten its agriculture unit just two years after the controversial Monsanto takeover.“It was already quite clear that the growth prospects of Monsanto had deteriorated over the last 2.5 years, though the magnitude of this decline is greater than expected,” Sebastian Bray, an analyst at Berenberg Bank, said by email.The pandemic has hurt demand for agricultural commodities and biofuel, exacerbating headwinds like trade tensions, competition and the African swine fever.The company’s crop business, which delivers just under half of sales, will face a “deeper than expected” impact that probably won’t improve in the near term, Bayer said in a statement. The company expects to take non-cash impairment charges in the mid to high-single-digit billion-euros range on assets in the agricultural business.Citi analysts cut their rating on Bayer to hold from buy. The “long suffering” buy recommendation had been based on the idea that the stock was cheap and a resolution to the Roundup litigation was near, Peter Verdult and Andrew Baum wrote in a note.“We were wrong,” they said, adding that concerns will probably intensify over Bayer’s long-term growth outlook.While completing midterm planning Wednesday, Bayer management decided to lower expectations for the crop division through 2021, and perhaps even into 2022, Baumann said on a call with investors.“It is totally clear that the impairment is driven by that lack of growth,” he said. “We cannot outgrow, to the extent of our original assumptions, a market that doesn’t grow at the level we need it to.”The company’s pharmaceutical arm, meanwhile, is facing patent expirations for two blockbuster medicines in the next few years while its pipeline of potential future products is regarded as weak.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.,

Bayer Slumps as Bleak Crop Outlook Undermines Monsanto Rationale(Bloomberg) — Bayer AG slumped after the agriculture and pharma giant said it would have to slash costs as the pandemic’s impact on farm commodities extends into next year, further undermining the rationale for its $63 billion purchase of Monsanto Co.The stock fell as much as 13% in German trading. Bayer, already reeling from a legal battle over its herbicide Roundup, late Wednesday said it would cut 1.5 billion euros ($1.8 billion) of annual costs and may also eliminate jobs and sell businesses.Chief Executive Officer Werner Baumann is confronting multiple challenges after getting his contract extended earlier this month. Besides Roundup, the German company faces slumping crop prices and demand for biofuel that threaten its agriculture unit just two years after the controversial Monsanto takeover.“It was already quite clear that the growth prospects of Monsanto had deteriorated over the last 2.5 years, though the magnitude of this decline is greater than expected,” Sebastian Bray, an analyst at Berenberg Bank, said by email.The pandemic has hurt demand for agricultural commodities and biofuel, exacerbating headwinds like trade tensions, competition and the African swine fever.The company’s crop business, which delivers just under half of sales, will face a “deeper than expected” impact that probably won’t improve in the near term, Bayer said in a statement. The company expects to take non-cash impairment charges in the mid to high-single-digit billion-euros range on assets in the agricultural business.Citi analysts cut their rating on Bayer to hold from buy. The “long suffering” buy recommendation had been based on the idea that the stock was cheap and a resolution to the Roundup litigation was near, Peter Verdult and Andrew Baum wrote in a note.“We were wrong,” they said, adding that concerns will probably intensify over Bayer’s long-term growth outlook.While completing midterm planning Wednesday, Bayer management decided to lower expectations for the crop division through 2021, and perhaps even into 2022, Baumann said on a call with investors.“It is totally clear that the impairment is driven by that lack of growth,” he said. “We cannot outgrow, to the extent of our original assumptions, a market that doesn’t grow at the level we need it to.”The company’s pharmaceutical arm, meanwhile, is facing patent expirations for two blockbuster medicines in the next few years while its pipeline of potential future products is regarded as weak.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage